Dr. Harry W. Saperstein, MD

Dr. Saperstein practices at Transpath in Canoga Park, California.

Dr. Saperstein's NPI, 1689674715, was assigned on July 29, 2005. Dr. Saperstein graduated from Keck School of Medicine of USC in 1977. Dr. Saperstein holds California license G37913.

Dr. Saperstein's primary practice is Transpath, at 21018 Osborne St, Ste 5, Canoga Park, CA 91304. The practice phone is (818) 993-1489.

Dr. Saperstein's primary practice is Transpath in Canoga Park, California. Dmand AI also links Dr. Saperstein to 1 physician office, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Saperstein practices, 2 sites in all. Vendor and product names are available with a free account.

Procedural dermatology is Dr. Saperstein's primary specialty in the NPI Registry, under taxonomy code 207NS0135X. Dr. Saperstein is board certified in dermatology by the American Board of Dermatology. Dr. Saperstein is licensed in California.

Dmand AI lists acne, acute skin infection, benign or precancerous skin growths, cancerous skin growth removal, cold sores or genital herpes, contact dermatitis, corns and calluses and facial skin infection among the conditions Dr. Saperstein treats.

CMS data shows 35,204 Medicare services from Dr. Saperstein across 35 procedure codes in 2024, for 1,873 Medicare patients. Medicare paid $1,450,884 for them. Every service was in an office.

CMS counts 1,873 Medicare patients who saw Dr. Saperstein in 2024. The largest group is 75 to 84, with 832 patients. 75% of them have high cholesterol, and 67% have high blood pressure. 11% are also on Medicaid. Their average risk score is 1.06, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Saperstein's median patient age at 77, with 47% women.

In 2024, Dr. Saperstein wrote 4,682 Medicare Part D claims for 1,268 patients. 96% of them were for generic drugs. CMS names the drug for 4,480 of them, across 37 drugs with 11 or more claims each, at $417,500 in total drug cost. In 2023, CMS named 4,546 claims across 37 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 75 out of 100 for Dr. Saperstein for performance year 2024, reported individually. Dr. Saperstein accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Saperstein as offering telehealth. CMS counts 6,560 procedures of removal of skin lesions by Dr. Saperstein, more than 99% of the clinicians it reports for that procedure.

Removal of tissue: 1 to 10 procedures (CMS shows small counts as a range)

Removal or shaving of skin growth: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 3 papers to Dr. Saperstein. Dr. Saperstein's most frequent co-authors are Susan P. Detwiler, MD and Marvin J. Rapaport, MD.

CMS Open Payments shows 616 general payments to Dr. Saperstein from 48 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 99% of the total. Sanofi and Genzyme US Companies paid the most, $1,315.

Dmand AI lists 5 awards for Dr. Saperstein, most recently Top Doctors:LA Area in 2013.

Dr. Saperstein graduated from Keck School of Medicine of USC in 1977. Dr. Saperstein is a member of AAD and ASDS.

Dr. Saperstein is in network with 6 carriers, including Aetna, Blue Cross Blue Shield of Michigan and Blue Cross Blue Shield of Massachusetts. Medicare plans come from the most carriers, 6. Check the plan with the practice before a visit.